Search

Your search keyword '"Pianko S"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Pianko S" Remove constraint Author: "Pianko S" Publisher united kingdom Remove constraint Publisher: united kingdom
18 results on '"Pianko S"'

Search Results

1. Retreatment with elbasvir, grazoprevir, sofosbuvir +/- ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.

2. Retreatment with elbasvir, grazoprevir, sofosbuvir +/- ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.

3. Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.

4. Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.

5. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

6. Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.

7. Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.

8. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

9. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

10. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

11. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.

12. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.

13. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.

14. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.

15. Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.

16. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.

17. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.

18. Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.

Catalog

Books, media, physical & digital resources